Predictors of secukinumab treatment response and continuation in axial spondyloarthritis

Le résumé fourni par la source

Objective: In patients with axial spondyloarthritis (axSpA) initiating secukinumab, we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), as well as treatment continuation after 12 months. Methods: From 11 European registries, patients with axSpA, who initiated secukinumab treatment in routine care, with available data on 6-month ASDAS and BASDAI assessments were included. Logistic regression analyses on multiply imputed baseline data were performed

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.